Ascendiant Capital Markets Issues Positive Forecast for Lucid Diagnostics (NASDAQ:LUCD) Stock Price

Lucid Diagnostics (NASDAQ:LUCD) had its price objective boosted by Ascendiant Capital Markets from $7.50 to $7.75 in a report released on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other brokerages have also weighed in on LUCD. Cantor Fitzgerald reiterated an “overweight” rating and set a $2.00 target price on shares of Lucid Diagnostics in a research note on Thursday, May 15th. Wall Street Zen downgraded shares of Lucid Diagnostics from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. Needham & Company LLC reissued a “buy” rating and set a $3.00 price objective on shares of Lucid Diagnostics in a report on Wednesday, May 14th. Finally, BTIG Research set a $2.00 price target on shares of Lucid Diagnostics in a report on Tuesday, March 25th. One analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Lucid Diagnostics presently has a consensus rating of “Moderate Buy” and a consensus price target of $3.55.

Lucid Diagnostics Trading Up 6.6%

LUCD stock opened at $1.29 on Friday. The stock has a market capitalization of $139.56 million, a PE ratio of -1.13 and a beta of 1.31. The stock’s 50 day simple moving average is $1.32 and its 200 day simple moving average is $1.17. Lucid Diagnostics has a 12-month low of $0.68 and a 12-month high of $1.80.

Institutional Trading of Lucid Diagnostics

Institutional investors have recently added to or reduced their stakes in the company. Berkshire Asset Management LLC PA purchased a new position in shares of Lucid Diagnostics during the first quarter worth approximately $30,000. Northwestern Mutual Wealth Management Co. purchased a new stake in Lucid Diagnostics during the 1st quarter valued at about $37,000. Cubist Systematic Strategies LLC acquired a new position in Lucid Diagnostics in the 1st quarter valued at about $39,000. LPL Financial LLC boosted its holdings in Lucid Diagnostics by 29.1% in the 4th quarter. LPL Financial LLC now owns 53,391 shares of the company’s stock valued at $44,000 after purchasing an additional 12,035 shares during the last quarter. Finally, Sunbelt Securities Inc. acquired a new position in Lucid Diagnostics in the 4th quarter valued at about $67,000. Institutional investors own 74.01% of the company’s stock.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.